Semaglutide May Lower Risk for Opioid Overdose in T2DM, Opioid Use Disorder
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 25, 2024 -- For patients with type 2 diabetes (T2D) and opioid use disorder (OUD), semaglutide is associated with a significantly lower risk for opioid overdose compared with other antidiabetic medications, according to a research letter published online Sept. 25 in JAMA Network Open.
William Wang, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues conducted an emulation target trial to compare the association of semaglutide versus other antidiabetic medications with opioid overdose risk among patients with comorbid T2D and OUD. The study included 33,006 eligible patients: 3,034 prescribed semaglutide and 29,972 prescribed other antidiabetic medications.
The researchers found that during one-year follow-up, semaglutide was associated with a significantly lower risk for opioid overdose compared with other antidiabetic medications, including other glucagon-like peptide 1 receptor agonists, with hazard ratios varying from 0.32 to 0.58. No difference between the groups was seen in the negative control outcome (medical encounters for congenital malformations, deformations, and chromosomal abnormalities).
"Semaglutide was associated with reduced opioid overdose risk in patients with comorbid T2D and OUD, suggesting its potential therapeutic value for preventing overdoses," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...
Previous Estimates of Illicit Opioid Use in the United States Underreported
WEDNESDAY, May 14, 2025 -- Illicit opioid use may be higher than previously reported in the United States, according to a study published online May 9 in JAMA Health...
Metabolic and Bariatric Surgery Increased in Adolescents From 2021 to 2023
WEDNESDAY, May 14, 2025 -- Despite the approval of second-generation antiobesity medications, metabolic and bariatric surgery (MBS) use among U.S. adolescents increased from 2021...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.